Abstract

Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice. Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice. Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production. Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice. Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production. In order to avoid the presence of the MOPC 21 heavy chain in the specific hybrids, another myeloma cell line (NSI/Ag4-1) has been used. This is a nonsecreting variant of the MOPC 21 myeloma which does not express heavy chains. Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice. Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production. In order to avoid the presence of the MOPC 21 heavy chain in the specific hybrids, another myeloma cell line (NSI/Ag4-1) has been used. This is a nonsecreting variant of the MOPC 21 myeloma which does not express heavy chains. Three anti-SRBC (probably of the μ, γ2b and γ1 classes, respectively) and two anti-2,4,6-trinitrophenyl (of the μ class antibody-producing hybrids have been repeatedly cloned. By random selection and by selection of specific clones according to their lytic activity (clone plaque selection), a number of different lines have been constructed. Such lines express different combinations of the four possible chains of each hybrid line: the myeloma γ and k chains and the specific antibody heavy and light chains. In three cases (Sp1, Sp2 and Sp7) it is shown that only the specific H and L combination has activity and that the myeloma chains are unable to substitute for them. In most cases lines have been derived which no longer express the MOPC 21 chains but only the specific antibody chains.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a combined system for selecting and annotating training data of a machine-learning model, comprising the model (12) and two databases (14, 16) comprising unannotated or annotated data, respectively, characterised in that the model is configured to select a set of unannotated data (20) that are most useful to annotate, to automatically annotate the most useful unannotated data (20), to receive at least one correction and/or validation of data annotation by an oracle (18) in order to provide validated data (24) stored in the second database (16), and to be retrained by the validated data of the second database (16) for the selection of the most useful unannotated data and for the interactive annotation.

IPC Classes  ?

• G06F 18/21 - Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation

Abstract

A growing body of evidence suggests that leukocytes infiltration and inflammation play a key role in the onset of fetal membrane rupture. The objective of our study was to evaluate serum CX3CL1/Fractalkine, a monocyte/macrophage chemoattractant expressed in both cytotrophoblasts and decidual cells, as a predictive biomarker for the occurrence of preterm premature rupture of membranes (PPROM).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to polymeric compounds of glucuronic acid having phenolic hydroxyl moieties (herein after designated by PGU-Ph) and more particularly to a method of hydrogelation of such compounds. The present invention also relates to the use of the hydrogel structures (particles, films or 3D-structures) obtained by this method, notably as three-dimensional cell culture material to support biological molecules used as active ingredients, cell colonisation or for tissue regeneration.

IPC Classes  ?

• A61K 9/06 - Ointments; Bases therefor
• A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• C08B 37/08 - Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• C08L 5/00 - Compositions of polysaccharides or of their derivatives not provided for in group or

Goods & Services

Probes for scientific use; scientific apparatus and instruments; laboratory apparatus for detecting genetic sequences; diagnostic apparatus, not for medical use. Probes for medical use; DNA testing apparatus for medical use; genetic testing apparatus for medical use; medical apparatus and instruments. Development of probes for biotechnological applications; scientific services; research in biotechnology; advice in biotechnology; research and development in the field of biotechnology; evaluation, assessment and research in scientific and technological fields carried out by researchers; DNA screening services for scientific research; research with respect to DNA sequencing technology; DNA analysis services for scientific research purposes; genetic research; genetic mapping for scientific use; scientific research in the field of genetics. Medical services; medical analyses; DNA analysis for medical purposes; medical and health services relating to DNA, genetics and genetic testing; genetic analysis for medical use; genetic consultation.

Abstract

Security lighting device (1) comprising a front face (3) for displaying a pictogram, a rear face and at least one thick wall (5) extending between the front face and the rear face, said security lighting device comprising first light means designed to illuminate the front face (3), said lighting device (1) being characterized in that it further comprises second light means installed on said at least one thick wall (5), said second light means being chosen such that the emitted light has a combination of colour and/or form adapted to influence the decision of the user on the chosen direction of evacuation according to their position in the environment.

IPC Classes  ?

• G09F 19/18 - Advertising or display means not otherwise provided for using special optical effects involving the use of optical projection means, e.g. projection of images on clouds
• G09F 13/04 - Signs, boards, or panels, illuminated from behind the insignia
• G09F 9/37 - Indicating arrangements for variable information in which the information is built-up on a support by selection or combination of individual elements in which the desired character or characters are formed by combining individual elements being movable elements

Abstract

Security lighting device (1) comprising a front face (3) for displaying a pictogram, a rear face and at least one thick wall (5) extending between the front face and the rear face, said security lighting device comprising first light means designed to illuminate the front face (3), said lighting device (1) being characterized in that it further comprises second light means installed on said at least one thick wall (5), said second light means being controlled such that the emitted light has a flashing frequency of between 5 Hz and 24 Hz adapted to influence the decision of the user on the chosen direction of evacuation.

IPC Classes  ?

• G09F 13/04 - Signs, boards, or panels, illuminated from behind the insignia
• G09F 9/37 - Indicating arrangements for variable information in which the information is built-up on a support by selection or combination of individual elements in which the desired character or characters are formed by combining individual elements being movable elements
• G09F 19/22 - Advertising or display means on roads, walls or similar surfaces, e.g. illuminated

Abstract

The present invention concerns the detection of DNA base oxidation via 8-OxodG immunoreactivity.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6841 - In situ hybridisation

Abstract

Limosilactobacillus mucosae Limosilactobacillus mucosae , or a lysate or culture supernatant thereof, for use in the prevention and/or treatment of disorders requiring an increase in GLP-1 production in a subject in need of GLP-1, the disorders being selected from (i) a disorder related to dysregulation of insulin sensitivity and/or blood glucose concentration and (ii) loss of muscle mass and/or muscle function.

IPC Classes  ?

• C12N 1/20 - Bacteria; Culture media therefor
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/225 - Lactobacillus
• C12R 1/23 - Lactobacillus acidophilus
• C12R 1/245 - Lactobacillus casei
• C12R 1/46 - Streptococcus
• C12R 1/85 - Saccharomyces
• C12R 1/865 - Saccharomyces cerevisiae

Abstract

The present invention relates to an ex-situ biomethanation method as well as to the device for implementing same. The invention relates to an ex-situ methane production method comprising the steps of placing in contact at least one methanogenic microorganism, a culture substrate and optionally a first culture medium in a gas/liquid bioreactor optionally comprising a second culture medium and producing methane by the reaction of incoming gases with the at least one methanogenic microorganism, characterised in that the culture substrate is optionally immobilised in the gas/liquid bioreactor; and the at least one methanogenic microorganism is fixed to the culture substrate; as well as to the device for carrying out the method.

IPC Classes  ?

• C12P 5/02 - Preparation of hydrocarbons acyclic
• C12M 1/107 - Apparatus for enzymology or microbiology with means for collecting fermentation gases, e.g. methane
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 1/20 - Bacteria; Culture media therefor
• C12P 39/00 - Processes involving microorganisms of different genera in the same process, simultaneously

Abstract

The present invention concerns a controlled gene therapy of ocular diseases. This technology can be used in gene therapy protocols and avoids the side effects resulting from a continuous and uncontrolled expression of a transgene.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/86 - Viral vectors

Abstract

A composition of yeast polysaccharides including β(1,6)-glucans, preferably also mannans and α-glucans. The yeast polysaccharides are extracted from yeast cell wall fragments. Typically, the β-glucans are β(1,6)-glucans. Also, a method for obtaining such a composition, including at least one step of fractionating a composition of yeast cell walls and extracting an insoluble fraction, and at least one step of extracting a soluble fraction from the insoluble fraction obtained in step a). Further, a composition with a human or veterinary therapeutic objective, for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms, as well as to its non-therapeutic use for improving intestinal comfort.

IPC Classes  ?

• A61K 31/716 - Glucans
• A61K 36/064 - Saccharomycetales, e.g. baker's yeast
• A61P 31/04 - Antibacterial agents

Abstract

The invention relates to a pipette tip (1, 1') comprising at least one wall portion (2, 2') having a conical shape that is rotationally symmetrical about axis (R), characterized in that said wall portion (2, 2') comprises at least one first wall (20, 20') continuing on a periphery of at least one portion of an inner surface, said first wall projecting from a base (200, 200') in contact with said inner surface to a vertex (201, 201') at an angle of between 40° and 140° with respect to said wall portion (2, 2').

IPC Classes  ?

• B01L 3/02 - Burettes; Pipettes

Abstract

A method of expanding a complex community of microorganisms is provided, an expanded complex community of microorganisms obtained by the method is provided, a pharmaceutical formulation comprising the expanded complex community of microorganisms is provided, and the use of the expanded complex community of microorganisms and the pharmaceutical formulation is provided.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• C12N 1/20 - Bacteria; Culture media therefor

Abstract

The invention relates to a method for bringing a virtual three-dimensional model of a target organ, which model is called the 3D model, into register with at least one image of said target organ in a scene, said image being obtained by an endoscope (12), the method in particular comprising: a step of predicting a position and orientation of the target organ relative to the scene; a step of superposing at least one current endoscope image with a see-through projection of the 3D model as a function of the predicted position and orientation, on a display device (18); a step of receiving a command indicating an alignment between the see-through projection of the 3D model and the image of the target organ in the current image; and a step of computing the position and orientation of the target organ in the current image relative to the scene.

IPC Classes  ?

• G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods

Abstract

The method comprises an optimization step involving calculating a figure of merit representative of the sensitivity of the selected response to first sequence variations in first design variables and second sequence variations in second design variables of the spaces and substructures, then calculating a gradient of the figure of merit, subsequently modifying first or second design variables of at least one of the first and second sequences depending on said gradient in order to improve the figure of merit, and repeating the optimization step as long as the figure of merit does not represent a set objective and/or is lower than a selected value, wherein the first P+S design variables of the first sequence and the second P+S design variables of the second sequence are substructure (3p) or space (4s) widths between substructures (3p), which widths are defined in one of three different directions of a three-dimensional space.

IPC Classes  ?

• G06F 30/20 - Design optimisation, verification or simulation

Abstract

The present invention concerns a human T cell or NK cell comprising a nucleic acid construct which comprises a transgene which is placed under the control of a regulatory polynucleotide inducible by a deficiency in at least one essential amino acid, and cellular immunotherapy employing said human T cell or NK cell.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 5/07 - Animal cells or tissues

Abstract

0D0TDD).

IPC Classes  ?

• G01N 21/53 - Scattering, i.e. diffuse reflection within a body or fluid within a flowing fluid, e.g. smoke
• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/06 - Investigating concentration of particle suspensions
• G01N 15/00 - Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G01N 33/18 - Water

Abstract

The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gas-dermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdennin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AA V2/8 vector expressing at least one USH1 gene product, preferably SANS.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 8/64 - Proteins; Peptides; Derivatives or degradation products thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• A61Q 19/08 - Anti-ageing preparations
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 35/761 - Adenovirus
• C12N 15/86 - Viral vectors
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to a dynamic model that allows the in vitro study of the intestinal permeability of a molecule of interest or active substance, preferably continuously coupled to an artificial dissolution or digestion device, as well as to the use and a method for implementing said device.

IPC Classes  ?

• G01N 13/00 - Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
• G01N 15/08 - Investigating permeability, pore volume, or surface area of porous materials
• G01N 33/483 - Physical analysis of biological material
• G01N 15/00 - Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials

Abstract

The present invention relates to a method for determining the properties of resistance to beta-lactam antibiotics of a strain of enterobacteria present in a biological sample, which method comprises the steps of: a) lysis of the bacteria and hydrolysis of the bacterial proteins in order to obtain a mixture of peptides, b) analysis of this mixture of peptides by targeted mass spectrometry coupled with reverse phase liquid chromatography, detection of at least one specific peptide of an enzyme exhibiting extended spectrum beta-lactamase (ESBL) activity being indicative of the resistance to beta-lactams of the strain of enterobacteria present in the biological sample, the method being characterised in that the analysis step (b) is carried out in the presence of an ion pairing reagent (IPR) added into the chromatography column or into the mixture of peptides.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
• C12Q 1/10 - Enterobacteria
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The invention concerns new peptidomimetic (or peptoid) molecules for the prevention and/or treatment of chronic pain, particularly that resulting from peripheral neuropathies.

IPC Classes  ?

• C07K 5/10 - Tetrapeptides
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The invention relates to a semi-automatic image segmentation system comprising a neural network (12) configured, for each iteration, to receive input data comprising at least one image (14) to be segmented and to provide output data comprising at least one mask (16) for segmenting each image, characterised in that it further comprises a user interaction loop (18) comprising a user interaction module (20) configured to provide at least one user mask representative of an interaction with a real user and/or a simulated user on each segmentation mask, the user interaction loop (18) being configured to provide, as input data for the neural network (12), each segmentation mask provided by the neural network from a past iteration of the neural network (12), referred to as the past segmentation mask, and the user mask associated with each past segmentation mask.

IPC Classes  ?

• G06T 7/10 - Segmentation; Edge detection
• G06V 10/22 - Image preprocessing by selection of a specific region containing or referencing a pattern; Locating or processing of specific regions to guide the detection or recognition
• G06V 10/26 - Segmentation of patterns in the image field; Cutting or merging of image elements to establish the pattern region, e.g. clustering-based techniques; Detection of occlusion
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding

Abstract

The invention relates to a method for real-time tracking of the pose of a camera with respect to a 3D model comprising a key-image database that comprises a first execution thread for estimating the current pose of the camera from a selected key image, characterised in that the method further comprises a step of analysing the quality of the estimation of the pose of the camera from the image stored in a buffer memory, and a step of analysing the sharpness of the image stored in the buffer memory from data representative of the movement of the camera, and if the quality of the estimation of the pose of the camera from the stored image and the sharpness of the stored image comply with predetermined criteria, a step of adding the image stored in the buffer memory to the key-image database, as a new key image.

IPC Classes  ?

• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods

Abstract

The invention relates to a method for real-time tracking of the pose of a camera with respect to a 3D model comprising a key-image database that comprises a first execution thread for estimating the current pose of the camera from a selected key image, characterised in that the method further comprises a step of analysing the quality of the estimation of the pose of the camera from the image stored in a buffer memory, and a step of analysing the sharpness of the image stored in the buffer memory from data representative of the movement of the camera, and if the quality of the estimation of the pose of the camera from the stored image and the sharpness of the stored image comply with predetermined criteria, a step of adding the image stored in the buffer memory to the key-image database, as a new key image.

IPC Classes  ?

• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments

Abstract

1233) spaced apart from one another and each comprising at least one sample holder for receiving at least one sample to be studied; - a light source (10) configured to illuminate the study zones (Z) and comprising at least one light-emitting diode lamp (30); - a study chamber (20) within which the support is housed, the chamber being configured so that, in each study zone, the irradiance of the radiation emitted by the light source is homogeneous and so that the study zones have different irradiances of said radiation between them.

IPC Classes  ?

• G01N 17/00 - Investigating resistance of materials to the weather, to corrosion or to light

Abstract

The present invention relates to compositions and methods for detecting muscle atrophy in a subject. The invention also provides novel biomarkers that allow in vitro or ex vivo detection of a loss of muscle mass in a subject. The invention also relates to the use of muscle atrophy as an indicator of the occurrence, or the risk of occurrence of a disease or a disorder in a subject. Furthermore, the invention relates to a kits and reagents for use in these methods.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to compositions and methods for detecting muscle atrophy in a subject. The invention also provides novel biomarkers that allow in vitro or ex vivo detection of a loss of muscle mass in a subject. The invention also relates to the use of muscle atrophy as an indicator of the occurrence, or the risk of occurrence of a disease or a disorder in a subject. Furthermore, the invention relates to a kits and reagents for use in these methods.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

A process for the dry synthesis of a luminophore of formula Ax[BFy]:C includes a stage of providing an initial composition comprising at least two synthetic precursors and at least one chemical doping source, a stage of heating the initial composition up to a fluorination temperature under an inert atmosphere or under vacuum, a stage of treatment under a fluorine atmosphere of the composition obtained on conclusion of the heating stage and a stage of returning to ambient temperature under an inert atmosphere. A composition comprising a luminophore of formula Ax[BFy]:C and obtained according to the synthetic process described above, the composition being devoid of hydrogen fluoride.

IPC Classes  ?

• C09K 11/61 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing fluorine, chlorine, bromine, iodine or unspecified halogen elements

Goods & Services

Scientific apparatus and instruments; Computer platforms, All in the field of gaming; Software, All in the field of gaming; Computer games in relation to the following fields: Farming, feed, Environment and Territory development; Computer software or platforms for finding a suitable game according to different criteria; Artificial intelligence software, in relation to the following fields: Games; Game development software; Computer application software featuring games and gaming; data storage media devices; Data processing systems; Database engines; Computer programmes for data processing. Playing cards in relation to the following fields: Farming, feed, Environment and Territory development; Games equipment in relation to the following fields: Farming, feed, Environment and Territory development; Game manuals and rules in relation to the following fields: Farming, feed, Environment and Territory development; Books in the fields of games and gaming; Advertising pamphlets. Games; Toys; Table-top games; Educational board games; Card games; Educational playing cards; Multi-part construction toys; Educational game pieces; Carrying equipment for educational games; Educational games, in relation to the following fields: Agriculture, food, environment and territory development; Electronic games, in relation to the following fields: Agriculture, food, environment and territory development; Boards for games; Models for use with role playing games. Teaching; Training; Entertainment services; Educational and training services relating to games in relation to the following fields: Farming, food, Environment and Territory development; Providing amusement arcade services; Organisation, arranging and conducting of educational games; Providing of information, in relation to the following fields: Educational games; Games library services; Game services provided online from a computer network; Library services and rental of media; Arranging of conferences and training workshops In the field of games; Games equipment rental; Providing facilities for playing live-action role-playing games; Conducting of cultural activities; Conducting of educational events; Organization of competitions [education or entertainment]; Organising events for entertainment purposes; Organisation of events for educational purposes; organization, arranging and conducting of conferences, congresses, seminars, colloquiums, symposiums and workshops (training); Conducting of educational seminars; Organising and conducting workshops and seminars; Conducting workshops and seminars. Technical assessments relating to design; Scientific research, in relation to the following fields: games; Scientific and technological services, in relation to the following fields: development of games, Mobilisation and evaluation of games; Computer software design, in relation to the following fields: games; development of computer software in the field of gaming; Conducting technical project studies, in relation to the following fields: games; Computer software design, in relation to the following fields: games; Design of games; Design of board-games; Design of game prototypes; Design of graphical game universes; Design of educational games, in relation to the following fields: Farming, feed, the environment and Territory development; programming of platforms and Software programming, in relation to the following fields: games; Computer programming of electronic game software; Testing of educational games; Game design consultancy.

Goods & Services

Scientific apparatus and instruments; Computer platforms, All in the field of gaming; Software, All in the field of gaming; Computer games in relation to the following fields: Farming, feed, Environment and Territory development; Computer software or platforms for finding a suitable game according to different criteria; Artificial intelligence software, All in the field of gaming; Game development software; Computer application software featuring games and gaming; data storage media devices; Data processing systems; Database engines; Computer programmes for data processing. Playing cards in relation to the following fields: Farming, feed, Environment and Territory development; Games equipment in relation to the following fields: Farming, feed, Environment and Territory development; Game manuals and rules in relation to the following fields: Farming, feed, Environment and Territory development; Books in the fields of games and gaming; Advertising pamphlets. Games; Toys; Table-top games; Educational board games; Card games; Educational playing cards; Multi-part construction toys; Educational game pieces; Carrying equipment for educational games; Educational games, in relation to the following fields: Agriculture, food, environment and territory development; Electronic games, in relation to the following fields: Agriculture, food, environment and territory development; Boards for games; Models for use with role playing games. Teaching; Training; Entertainment services; Educational and training services relating to games in relation to the following fields: Farming, food, Environment and Territory development; Providing amusement arcade services; Organisation, arranging and conducting of educational games; Providing of information, in relation to the following fields: Educational games; Games library services; Game services provided online from a computer network; Library services and rental of media; Arranging of conferences and training workshops In the field of games; Games equipment rental; Providing facilities for playing live-action role-playing games; Conducting of cultural activities; Conducting of educational events; Organization of competitions [education or entertainment]; Organising events for entertainment purposes; Organisation of events for educational purposes; organization, arranging and conducting of conferences, congresses, seminars, colloquiums, symposiums and workshops (training); Conducting of educational seminars; Organising and conducting workshops and seminars; Conducting workshops and seminars. Technical assessments relating to design; Scientific research, in relation to the following fields: games; Scientific and technological services, in relation to the following fields: development of games, Mobilisation and evaluation of games; Computer software design, in relation to the following fields: games; development of computer software in the field of gaming; Conducting technical project studies, in relation to the following fields: games; Computer software design, in relation to the following fields: games; Design of games; Design of board-games; Design of game prototypes; Design of graphical game universes; Design of educational games, in relation to the following fields: Farming, feed, the environment and Territory development; programming of platforms and Software programming, in relation to the following fields: games; Computer programming of electronic game software; Testing of educational games; Game design consultancy.

Abstract

The present invention relates to a galenic form for oral controlled release of a substance of interest, said galenic form comprising a combination of biodegradable and biocompatible polymer excipients, said combination of polymer excipients comprising at least one denatured or non-denatured protein, at least one polysaccharide and baobab fruit pulp. It also relates to a controlled-release pharmaceutical or food composition based on such a galenic form, and also to a process for preparing such a composition.

IPC Classes  ?

• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A23K 10/37 - Animal feeding-stuffs from material of fungal origin, e.g. mushrooms from waste material
• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• A23K 20/163 - Sugars; Polysaccharides
• A23K 50/50 - Feeding-stuffs specially adapted for particular animals for rodents
• A23L 29/231 - Pectin; Derivatives thereof
• A23L 29/256 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/17 - Amino acids, peptides or proteins
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A23L 33/19 - Dairy proteins
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/734 - Alginic acid

Abstract

The present invention relates to a composition comprising bacteria of the strain L. casei SGC-K deposited at the National Collection of Cultures of Microorganisms in the Institut Pasteur, 8 March 2021, under no. CNCM 1-5663. The invention also relates to the nutritional and therapeutic uses of said composition.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a composition comprising bacteria of the strain L. casei SGC-K deposited at the National Collection of Cultures of Microorganisms in the Institut Pasteur, 8 March 2021, under no. CNCM 1-5663. The invention also relates to the nutritional and therapeutic uses of said composition.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to polymeric compounds of glucuronic acid having phenolic hydroxyl moieties (herein after designated by PGU-Ph) and more particularly to a method of hydrogelation of such compounds. The present invention also relates to the use of the hydrogel structures (particles, films or 3D-strucutres) obtained by this method, notably as three-dimensional cell culture material to support biological molecules used as active ingredients, cell colonisation or for tissue regeneration.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
• A61L 27/52 - Hydrogels or hydrocolloids
• C08L 5/00 - Compositions of polysaccharides or of their derivatives not provided for in group or
• C08B 37/00 - Preparation of polysaccharides not provided for in groups ; Derivatives thereof
• C08B 37/08 - Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• C08L 5/08 - Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The present invention concerns novel pyridin-2(1H)one derivatives, their process of preparation and their use in therapeutics, in particular as agents for treating and/or preventing pain.

IPC Classes  ?

• C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
• C07D 213/73 - Unsubstituted amino or imino radicals
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

Invention belongs to the field of medicine, more specifically the field of cancer prognostic and therapeutic management. Invention relates to an in vitro method of identifying an oncogenic transformation in a tissue sample from a subject suspected to be afflicted with a cancer, said method comprising a step of labelling said tissue sample for CENP-A protein or for an homolog thereof and a step of determining a nuclear pattern of CENP-A labelling in cells from said tissue sample. Invention also relates to a kit for implementing said method.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present application relates to a composition of yeast polysaccharides comprising β-(1,6)-glucans, preferably also mannans and α-glucans, characterized in that said yeast polysaccharides are extracts of yeast wall fragments. Typically, the β-glucans are β-(1,6)-glucans. It also relates to a method for obtaining such a composition comprising at least one step of fractionating a yeast wall composition and extracting an insoluble fraction, and at least one step of extracting a soluble fraction from the insoluble fraction obtained in step a). The present application lastly relates to a composition with a human or veterinary therapeutic objective, for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms and also to the non-therapeutic use thereof for improving intestinal comfort.

IPC Classes  ?

• A61K 36/064 - Saccharomycetales, e.g. baker's yeast
• A61K 8/73 - Polysaccharides
• A61K 31/716 - Glucans
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 31/04 - Antibacterial agents

Abstract

1ab243165167166)alkyl; for use as radiosensitizer.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Glossomastix Glossomastix as a texturizing agent.

IPC Classes  ?

• A61K 8/9706 - Algae
• A61Q 5/00 - Preparations for care of the hair
• A61Q 19/00 - Preparations for care of the skin
• A61K 8/9711 - Phaeophycota or Phaeophyta [brown algae], e.g. Fucus

Abstract

The present application relates to novel depolymerized exopolysaccharides derived from microalgae, the method for obtaining same from microalgae, and their use for increasing the production of collagen and/or hyaluronic acid, in order to delay the effects of skin ageing.

IPC Classes  ?

• C12N 1/12 - Unicellular algae; Culture media therefor
• A61K 8/73 - Polysaccharides
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12R 1/89 - Algae

Abstract

The invention relates to a method for processing images acquired by an endoscope (12), in order to automatically estimate the position of at least one trocar (58) arranged on a wall (56) of the body of a patient, each trocar (58) being configured to enable the passage of a tool (54) through the wall in order to access a cavity (50) of the body of the patient, characterized in that it comprises a step of acquiring images of the abdominal cavity (50) of the patient by the endoscope (12), each of the images representing at least one tool (54) passing through each trocar (58), a step of determining, on the basis of the images, the position and orientation of the tool (54) relative to the position of the endoscope (12), a step of estimating, on the basis of the images, the position of each trocar (58) on the basis of at least two positions and orientations of the tool (54).

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
• A61B 1/313 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
• A61B 17/34 - Trocars; Puncturing needles
• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis

Abstract

A method optimises a structure comprising P substructures which are separated by S spaces and each comprise at least one layer of a material so that said structure has a selected response to a selected electromagnetic excitation. The method comprises an optimisation step (110-230) involving calculating a figure of merit representative of the sensitivity of the selected response to first sequence variations in first design variables and second sequence variations in second design variables of the spaces and substructures, then calculating a gradient of the figure of merit, subsequently modifying first or second design variables of at least one of the first and second sequences depending on said gradient in order to improve the figure of merit, and repeating the optimisation step as long as the figure of merit does not represent a set objective and/or is lower than a selected value, wherein the first P+S design variables of the first sequence and the second P+S design variables of the second sequence are substructure (3p) or space (4s) widths between substructures (3p), which widths are defined in one of three different directions of a three-dimensional space.

IPC Classes  ?

• G06F 30/20 - Design optimisation, verification or simulation
• G06F 111/10 - Numerical modelling

Goods & Services

Scientific apparatus and instruments; Optical apparatus and instruments; Instructional and teaching apparatus and instruments; Optical apparatus and instruments for tracking the path of light rays. Training in the use of scientific instruments and apparatus; Training, in relation to the following fields: Handling of optical apparatus and instruments; Training, in relation to the following fields: Handling of teaching apparatus and instruments; Training, in relation to the following fields: Handling of optical apparatus and instruments for tracking the path of light rays.

Abstract

The present invention concerns a method of expanding a complex community of microorganisms, an expanded complex community of microorganisms obtained by said method, a pharmaceutical formulation comprising said expanded complex community of microorganisms and the use of said expanded complex community of microorganisms and said pharmaceutical formulation.

IPC Classes  ?

• A61K 35/66 - Microorganisms or materials therefrom
• A61K 35/74 - Bacteria

Abstract

The present invention concerns a method of expanding a complex community of microorganisms, an expanded complex community of microorganisms obtained by said method, a pharmaceutical formulation comprising said expanded complex community of microorganisms and the use of said expanded complex community of microorganisms and said pharmaceutical formulation.

IPC Classes  ?

• A61K 35/66 - Microorganisms or materials therefrom
• A61K 35/74 - Bacteria

Goods & Services

Analysis and assessment of animal semen, for scientific research purposes in the field of animal fertility, namely, analyses of seminal and sperm parameters for seed assessment, for the artificial insemination industry for production animals and/or for species conservation programs. Medical analyses for the diagnosis and treatment of people, assessment and treatment of human fertility, namely, analysis of seminal and sperm parameters for the assessment of seeds, for medically assisted procreation in a fertility clinic.

Abstract

The invention relates to novel peptidomimetic molecules (or peptoids) for the prevention and/or treatment of chronic pain, in particular pain resulting from peripheral neuropathies.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61K 38/02 - Peptides of undefined number of amino acids; Derivatives thereof
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Goods & Services

Analysis and assessment of animal semen, for scientific research purposes in the field of animal fertility, namely, analyses of seminal and sperm parameters for seed assessment, for the artificial insemination industry for production animals and/or for species conservation programs Medical analyses for the diagnosis and treatment of people, assessment and treatment of human fertility, namely, analysis of seminal and sperm parameters for the assessment of seeds, for medically assisted procreation in a fertility clinic

Abstract

A method of predicting resistance to anti-PD1 therapy in a subject suffering from cancer comprising the steps of a) determining, from a biological sample from a subject, in particular a feces or colonic biopsy sample from the subject, the presence of a bacterial pks island, b) predicting from the result of step a) that the subject is likely to be resistant to anti-PD1 therapy, is provided. Methods of treating cancer in a subject by assessing the presence or absence of bacterial pks island in a biological sample from a subject, in particular a feces or colonic biopsy sample from the subject and administering to the subject an anti-cancer therapy are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

The present invention relates to a method for detecting and/or tracking and/or characterizing the formation of a biofilm. The present invention also relates to a device for detecting and/or characterizing the formation of a biofilm suitable for implementing the method. The present invention can be used in particular in the analytical fields, in biological and enzymological research, in the pharmaceutical field and/or in the medical field.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

1234577 groups are chosen from the group consisting of: H, halogen, and alkyl; for use as radiosensitizer.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a fluorination process consisting in bringing an inorganic compound M into contact with an atmosphere comprising difluorine gas, the inorganic compound M being a garnet based on the elements Li, La, Zr, A and O and for which the relative composition of the Li, La, Zr and A cations corresponds to the formula (I): LixLa3ZrzAw.

IPC Classes  ?

• C01G 25/00 - Compounds of zirconium

Abstract

x3zww.

IPC Classes  ?

• C01G 25/00 - Compounds of zirconium

Abstract

xyxyy]:C and obtained according to the synthesis process described above, the composition being free of hydrogen fluoride.

IPC Classes  ?

• C09K 11/61 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing fluorine, chlorine, bromine, iodine or unspecified halogen elements

Abstract

Eggerthella, for the isolation and/or culture of an archaeon of the order of commensal clade Methanomassiliicoccales, and a pure, isolated archaeon Methanomethylophilus alvus Mx-05. It also concerns a culture method of an archaeon of the order of commensal clade Methanomassiliicoccales.

IPC Classes  ?

• C12N 1/20 - Bacteria; Culture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Abstract

HH)one derivatives, their process of preparation and their use in therapeutics, in particular as agents for treating and/or preventing pain.

IPC Classes  ?

• A61P 23/00 - Anaesthetics
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Abstract

The invention relates to the production of a microtextured anode and to the use of this anode in an electrochemical cell for the electrolytic production of gaseous fluorine in a bath of molten fluorinated salts.

IPC Classes  ?

• C25B 11/12 - Electrodes based on carbon
• C25B 1/24 - Halogens or compounds thereof
• C25B 11/02 - Electrodes; Manufacture thereof not otherwise provided for characterised by shape or form

Goods & Services

Medical simulators [teaching aids]; Software; Teaching robots. Artificial teeth. Education services relating to health; Training.

Abstract

2 being injected into the enclosure at a partial pressure between 100 Pa and 10000 Pa and step (c) being done at a temperature between 0° C. and 100° C. A pipette tip comprising a filter modified by the fluorination method, a method for producing such a tip, as well as a withdrawing pipette equipped with such a tip.

IPC Classes  ?

• B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres
• B01L 3/02 - Burettes; Pipettes
• C08L 23/28 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers modified by chemical after-treatment by reaction with halogens or halogen-containing compounds

Abstract

The present invention concerns the rapid and selective detection of pathogenic bacteria expressing a lectin-type adhesin in a biological environment using a cellulose support functionalized with a ligand of a lectin-type adhesin, and its use for the diagnostic of infection with pathogenic bacteria expressing a lectin- type adhesin, for example in the context of Crohn's disease or in urinary tract infections.

IPC Classes  ?

• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61P 31/04 - Antibacterial agents
• A61K 47/38 - Cellulose; Derivatives thereof
• A61P 35/00 - Antineoplastic agents

Abstract

Lycium barbarum. This composition is in particular useful as a nutritional product or health product to prevent and/or combat fat and/or carbohydrate metabolism disorders in Humans or animals.

IPC Classes  ?

• A61K 36/287 - Chrysanthemum, e.g. daisy
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/455 - Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
• A61K 31/51 - Thiamines, e.g. vitamin B1
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 33/24 - Heavy metals; Compounds thereof
• A61K 33/30 - Zinc; Compounds thereof
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• A61K 36/67 - Piperaceae (Pepper family), e.g. Jamaican pepper or kava
• A61K 36/815 - Lycium (desert-thorn)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

The invention relates to a composition comprising at least one specific mixture of molecules for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel diseases in humans or animals.

IPC Classes  ?

• A23L 33/11 - Plant sterols or derivatives thereof, e.g. phytosterols
• A61K 31/05 - Phenols
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 36/287 - Chrysanthemum, e.g. daisy
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• A61K 36/67 - Piperaceae (Pepper family), e.g. Jamaican pepper or kava

Abstract

The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 8/64 - Proteins; Peptides; Derivatives or degradation products thereof
• A61K 35/761 - Adenovirus
• C12N 15/86 - Viral vectors
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• A61Q 19/08 - Anti-ageing preparations
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to the use of an aldolase when carrying out a process comprising multiple successive crossed aldol reactions.

IPC Classes  ?

• C12P 7/26 - Ketones
• C07F 9/09 - Esters of phosphoric acids
• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
• C12P 17/04 - Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin
• C12P 17/06 - Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
• C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin

Abstract

Disclosed is a method for executing a processing operation consisting of a set of computing agents on a data processing platform, each agent associating a routine with methods for executing the routine, and the method comprising - a step (S1) of providing a representation of the computer processing operation in the form of a skeleton composed of an oriented set of nodes, each node corresponding to one of the computing agents; - a step (S2) of decomposing the skeleton in an exhaustive graph in which the set of software modules that can implement each of the agents is determined, and, if applicable, each node is replaced by a group of nodes, each node of the group corresponding to a software module that can implement the agent corresponding to the replaced node; - a step (S3) of assigning costs to each node in the exhaustive graph, and to each transition between nodes; - a step (S4) of determining an optimal graph by maintaining a path of the graph minimising the costs; - an execution step (S5) consisting in calling, in an ordered manner, the software modules corresponding to the optimal graph, and ensuring the translations and synchronisation of data between each call.

IPC Classes  ?

• G06F 9/50 - Allocation of resources, e.g. of the central processing unit [CPU]

Abstract

The present invention relates to a method for preparing phosphorylated keto polyols by biocatalysis and uses thereof.

IPC Classes  ?

• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
• C07F 9/09 - Esters of phosphoric acids
• C12P 7/26 - Ketones
• C07H 1/02 - Phosphorylation
• C07H 3/02 - Monosaccharides
• C07H 11/04 - Phosphates; Phosphites; Polyphosphates

Abstract

The invention relates to a mobile manipulator module (1) intended to function independently, and in a cooperative manner with at least one other mobile manipulator module, having a frame (3) on which there are mounted at least one means of locomotion (21) and at least one operational means (42) that are linked to the frame (3) by at least one locomotion kinematic chain and at least one operational kinematic chain, respectively.

IPC Classes  ?

• B25J 5/00 - Manipulators mounted on wheels or on carriages
• B25J 15/00 - Gripping heads
• B25J 9/06 - Programme-controlled manipulators characterised by multi-articulated arms
• B25J 9/00 - Programme-controlled manipulators

Abstract

A method of predicting resistance to anti-PD1 therapy in a subject suffering from cancer comprising the steps of a) determining, from a biological sample from a subject, in particular a feces or colonic biopsy sample from the subject, the presence of a bacterial pks island, b) predicting from the result of step a) that the subject is likely to be resistant to anti-PD1 therapy, is provided. Methods of treating cancer in a subject by assessing the presence or absence of bacterial pks island in a biological sample from a subject, in particular a feces or colonic biopsy sample from the subject and administering to the subject an anti-cancer therapy are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to a method for detecting and/or monitoring and/or characterising the formation of a biofilm. The present invention also relates to a device for detecting and/or characterising the formation of a biofilm which is capable of implementing the method. The present invention is particularly used in the fields of analysis, biological and enzymological research, and in the pharmaceutical and/or medical fields.

IPC Classes  ?

• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention concerns an implant material for filling in bone defects, bone regeneration and bone tissue engineering, an implant comprising this material, and a method for manufacturing such an implant material. The implant material of the invention comprises a hybrid material doped with an osteoinductive nutrient N comprising: a bioactive glass M made from SiO2 and CaO, optionally containing P2O5 and/or optionally doped with strontium, and a biodegradable polymer P, this hybrid material being doped with an osteoinductive nutrient N. The invention is applicable, in particular, in the medical field.

IPC Classes  ?

• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials

Abstract

2255 and/or optionally doped with strontium, and a biodegradable polymer P, this hybrid material being doped with an osteoinductive nutrient N. The invention is applicable, in particular, in the medical field.

IPC Classes  ?

• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials

Abstract

Gastro-intestinal release capsule intended for oral use in a method for desensitizing and/or inducing tolerance in a peanut-allergic subject or, alternatively, for diagnosing a peanut allergy in a subject. The capsule has a shell and a core, the core has a composition of peanut including peanut, at least one oil, at least one first pulverulent excipient and, optionally, at least one second prebiotic excipient. The capsule is provided and ingested in an unopened form.

IPC Classes  ?

• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• A61K 47/02 - Inorganic compounds
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 37/08 - Antiallergic agents

Abstract

stabilization means adapted to stabilize the position of the printing head by a gyroscopic effect. The printing device enables the control of the printing of a structure to be printed, in particular the position of the printing head, to reduce the labor costs and the time to install such a device on a standard crane provided with a hook.

IPC Classes  ?

• B33Y 10/00 - Processes of additive manufacturing
• E04B 1/35 - Extraordinary methods of construction, e.g. lift-slab, jack-block
• B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• E04B 1/16 - Structures made from masses, e.g. concrete, cast or similarly formed in situ with or without making use of additional elements, such as permanent forms, sub-structures to be coated with load-bearing material
• E04G 21/04 - Devices for both conveying and distributing

Abstract

The invention relates to a bacteria of the Streptococcus thermophilus species with reference CNRZ160 for use in the prevention and/or treatment of intestinal inflammation in an individual.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/12 - Antidiarrhoeals
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Streptococcus thermophilusStreptococcus thermophilus species with reference CNRZ160 for use in the prevention and/or treatment of intestinal inflammation in an individual.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 1/12 - Antidiarrhoeals
• C12R 1/46 - Streptococcus

Abstract

The invention relates to an active pharmaceutical ingredient consisting exclusively of the combination of (1S,3R,4R,5R)-3-{[(2E)-3-(3,4-)dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid and of methyl (2S,3E,4S)-4-{2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl}-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate for use as a drug or veterinary product, particularly in the prevention and/or treatment of pathological disorders of carbohydrate and/or lipid metabolism.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Goods & Services

Electronic databases recorded on computer media; Data and file management and database software; Educational computer applications; Downloadable software applications; Educational mobile applications; Machine learning software for healthcare; Computer software for authorising access to data bases; Interfaces for computers; Computer software, recorded; Software and applications for mobile devices; Interactive computer software; Computer software platforms, recorded or downloadable; Computer software platforms; Recorded computer programs; Data processing programs; Data recorded electronically; Recorded data files; Information technology and audio-visual, multimedia and photographic devices; Storage apparatus for computer data. Provision of teleconferencing facilities for educational purposes; Providing access to databases in computer networks; Provision of access to data or documents stored electronically in central files for remote consultation; Data bank interconnection services; Transmission of digital files; On-line transmission of electronic publications; Data transmission and data broadcasting; Electronic transmission of images, photographs, graphic images and illustrations over a global computer network; Electronic transmission of data; Broadcasting of audiovisual and multimedia content via the Internet; Communications by television for meeting; Providing video conferencing services; Arranging [provision] of electronic conferencing services; Communications services for the exchange of data in electronic form; Telecommunications services to obtain information from data banks; Teleconferencing and video conferencing services; Electronic transmission of information (Services for the -); Digital transmission services for audio and video data; Videoconferencing; Data transmission for others; Network transmission of sounds, images, signals and data; Electronic transmission and retransmission of sounds, images, documents, messages and data; Digital transmission of data. Providing of training; Arranging and conducting of conferences, congresses and symposiums; Conducting of exhibitions for educational purposes; Publication of electronic books and journals online. Scientific research; Software design and development; Research and development for others; Design, maintenance, development and updating of computer software; Digitization of documents; Cloud computing; Electronic data storage.

Abstract

The invention relates to a method for fluorinating a filter (26) for a pipette tip (20), said filter (26) being made of a solid porous structure made of polyolefin. According to the invention, the method comprises the following steps: (a) placing the filter (20) in an enclosure, (b) creating a vacuum in the enclosure, and (c) bringing the filter (20) into contact with a fluorination agent injected into the enclosure in a gaseous state, the fluorination agent being made up of difluorine F2 , the difluorine F2 being injected into the enclosure at a partial pressure between 100Pa and 10000Pa and step (c) being done at a temperature between 0°C and 100°C. The invention also relates to a pipette tip (26) comprising a filter (20) modified by said fluorination method, a method for producing such a tip (26), as well as a withdrawing pipette equipped with such a tip (26).

IPC Classes  ?

• B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres

Abstract

The present invention relates to a spectral method for processing marking images in order to extract therefrom fields of movements and of deformations on the surface of objects, said marking being of the check pattern type, and in that said method is implemented in the Fourier space, by estimating a change of phases between a reference image and a deformed image, said change of phases at any point of the check pattern marking being proportional to the first order of the sought movement, said phases being obtained directly in each pixel of said check pattern marking. This estimate of the movement is subsequently refined with a fixed point algorithm. The present invention also relates to a system for processing marking images in order to extract therefrom fields of movements and of deformations on the surface of objects.

IPC Classes  ?

• G06T 7/262 - Analysis of motion using transform domain methods, e.g. Fourier domain methods
• G06T 7/00 - Image analysis

Abstract

2,22 being injected into the enclosure at a partial pressure between 100Pa and 10000Pa and step (c) being done at a temperature between 0°C and 100°C. The invention also relates to a pipette tip (26) comprising a filter (20) modified by said fluorination method, a method for producing such a tip (26), as well as a withdrawing pipette equipped with such a tip (26).

IPC Classes  ?

• B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres

Abstract

A method of manufacturing nanoparticles of a photoluminescent material, including the successive steps of: a) forming nanometer-range particles of said photoluminescent material; b) forming a dispersion containing the particles in a non-aqueous solvent, the dispersion further containing at least one surface agent; c) placing the dispersion in an autoclave at a pressure in the range from 2 MPa to 100 MPa; and d) recovering the particles.

IPC Classes  ?

• C09K 11/77 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/08 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials

Abstract

The invention relates to a composition comprising at least one specific mixture of molecules for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel diseases in humans or animals.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/28 - Dragees; Coated pills or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/287 - Chrysanthemum, e.g. daisy
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• A61K 36/67 - Piperaceae (Pepper family), e.g. Jamaican pepper or kava
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention concerns a method for isolating an archaebacterium of order Methanomassiliicoccales of the commensal clade, the use of a culture and/or isolation medium comprising a sterile extract of a bacterial culture of a bacterium of the Eggerthella genus, for isolating and/or culturing an archaebacterium of order Methanomassiliicoccales of the commensal clade, and a pure isolated Methanomethylophilus alvus Mx-05 archaebacterium. It also concerns a method for culturing an archaebacterium of order Methanomassiliicoccales of the commensal clade.

IPC Classes  ?

• C12N 1/20 - Bacteria; Culture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Abstract

Olea europaea. This composition is particularly useful as a nutritional product or health product for preventing and/or combating carbohydrate and/or fat metabolism disorders in humans and animals.

IPC Classes  ?

• A61K 36/287 - Chrysanthemum, e.g. daisy
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• A61K 36/67 - Piperaceae (Pepper family), e.g. Jamaican pepper or kava
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/28 - Dragees; Coated pills or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/455 - Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
• A61K 31/51 - Thiamines, e.g. vitamin B1
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 33/30 - Zinc; Compounds thereof

Abstract

The present invention relates to a method for preparing phosphorylated keto polyols by biocatalysis and uses thereof.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
• C07H 3/02 - Monosaccharides
• C12P 7/26 - Ketones

Abstract

The invention relates to a method for predicting the risk of developing acute respiratory distress syndrome (ARDS). Prediction of ARDS remains challenging despite available clinical scores. The inventors aimed to assess soluble isoforms and gene variants of the receptor for advanced glycation end-products (RAGE), as predictors of ARDS in a high-risk population. The inventors conducted a multicenter, prospective study including 500 adult patients with at least one ARDS risk factor upon admission to intensive care units. Plasma soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) were measured at baseline and 24 hours later, and four RAGE single nucleotide polymorphisms (SNPs). The primary outcome was ARDS development within seven days. Higher baseline and day one plasma sRAGE and the RAGE rs2070600 SNP were independently associated with an increased rate of ARDS development. Thus, the invention relates to a method for predicting the risk of having or developing ARDS in a patient in need thereof, comprising the step of determining the expression level of Plasma sRAGE and/or detecting RAGE SNP rs2070600 in a biological sample obtained from said patient.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Lycium barbarum. This composition is in particular useful as a nutritional product or health product to prevent and/or combat fat and/or carbohydrate metabolism disorders in Humans or animals.

IPC Classes  ?

• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 36/287 - Chrysanthemum, e.g. daisy
• A61K 36/815 - Lycium (desert-thorn)
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/455 - Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
• A61K 31/51 - Thiamines, e.g. vitamin B1
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 33/24 - Heavy metals; Compounds thereof
• A61K 33/30 - Zinc; Compounds thereof
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 36/67 - Piperaceae (Pepper family), e.g. Jamaican pepper or kava
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

3 comprises a radical R.

IPC Classes  ?

• C07F 9/10 - Phosphatides, e.g. lecithin
• C07C 69/587 - Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
• C07C 69/017 - Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

The present invention concerns a mobile 3D printing device (TDPD0) that prints by adding material, intended to be attached to a lifting device (LD) with a single hoisting cable or chain, the mobile 3D printing device (TDPD0) comprising: - a printing head (2) suitable for receiving the material and depositing it; - attachment means (3) suitable for connecting the printing head (2) to a lifting device (LD); and - stabilising means (MS) suitable for stabilising the position of the printing head (2) by gyroscopic effect. Such a device makes it possible to control the printing of the structure to be printed (200), in particular the position of the printing head (2), and to reduce labour costs and the time required for installation on a lifting device (LD) such as a standard crane provided with a hook (4).

IPC Classes  ?

• B28B 1/00 - Producing shaped articles from the material
• E04B 1/35 - Extraordinary methods of construction, e.g. lift-slab, jack-block
• E04G 21/04 - Devices for both conveying and distributing
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
• B29C 64/00 - Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering

Abstract

The present invention relates to an integrated circuit (4) for detecting radiation receiving, over a plurality of input channels, signals arising from radiation detectors, characterized in that said circuit includes, for each input channel, a means (10) for detecting radiation generating a detection signal when the amplitude of the signal at the input on the channel under consideration exceeds a reference value, and a plurality of analog memory units storing, at the moment of generation of said detection signal, the amplitude of the electrical signal present on an input channel and time information representative of the time of detection of the radiation, the integrated circuit further including an output port transmitting, out of said circuit, the stored analog signals and a trigger signal indicating the generation of a detection signal by each detection means.

IPC Classes  ?

• G01T 1/16 - Measuring radiation intensity
• H04N 5/30 - Transforming light or analogous information into electric information
• H04N 5/32 - Transforming X-rays

Abstract

The subject matter of the invention is a pharmaceutical active ingredient consisting exclusively of the combination of (lS,3R,4R,5R)-3-{[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid and methyl (2S,3E,4S)-4-{2-[2-(3,4- dihydroxyphenyl)ethoxy]-2-oxoethyl}-3-ethylidene-2-(P-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate for use as a medicine or veterinary product, in particular in the prevention and/or treatment of pathological carbohydrate and/or lipid metabolism disorders.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The subject matter of the invention is a pharmaceutical active ingredient consisting exclusively of the combination of (lS,3R,4R,5R)-3-{[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid and methyl (2S,3E,4S)-4-{2-[2-(3,4- dihydroxyphenyl)ethoxy]-2-oxoethyl}-3-ethylidene-2-(P-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate for use as a medicine or veterinary product, in particular in the prevention and/or treatment of pathological carbohydrate and/or lipid metabolism disorders.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention concerns a method for inspecting a surface, in particular the hull of a boat, comprising the following steps: a) acquiring images in two-dimensions also comprising point clouds in three dimensions of a surface to be inspected from at least two stations situated in different positions, said images having at least one area of overlap, b) constructing, in three dimensions, said surface to be inspected in a reference frame from the various acquired images, c) displaying said surface to be inspected in three dimensions from one of said stations and defining at least a first area to be processed, d) displaying said first area to be processed according to another of said stations and determining at least a second area to be processed, e) associating each of said first and second areas to be processed with at least one processing weighting coefficient, said weighting coefficient enabling the state of said first and second areas to be processed to be categorised according to quantitative and/or qualitative factors, f) determining the surface areas of said first and second areas to be processed, and, g) obtaining, at least from said determined surface areas and said first and second areas to be processed, a total surface to be processed.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 19/00 - Manipulating 3D models or images for computer graphics

Abstract

Gastrointestinal release capsule for use in a method for desensitising and/or inducing tolerance in a patient with a peanut allergy 5 Gastrointestinal release capsule for use in a method for desensitising and/or inducing tolerance in a patient with a peanut allergy, or alternatively for diagnosing a peanut allergy in a patient, said capsule comprising a shell and a core, said core comprising a 10 peanut composition comprising the peanut, at least one oil, at least one first pulverulent excipient, and optionally at least one second prebiotic excipent; said capsule being supplied and ingested in a non-open form. 1

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 35/35 - Fat tissue; Adipocytes; Stromal cells; Connective tissues 
• A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/35 - Allergens

Abstract

The invention relates to a method for determining extrinsic parameters of a perception system integrated into a vehicle (100) that travels a path and that comprises a set of rangefinders (L1, L2) that deliver frame streams to a processing device (110), this method being characterised by the determination of calibration parameters of at least one video camera (C1, C2) belonging to said perception system, and the determination of the position of the vehicle as a function of time and of these parameters, and furthermore comprising the detection of landmarks within the frame streams corresponding to landmarks in the real world, then determining extrinsic parameters that minimise a cost function measuring discrepancies between the detected landmarks associated with the same landmarks in the real world.

IPC Classes  ?

• G06T 7/80 - Analysis of captured images to determine intrinsic or extrinsic camera parameters, i.e. camera calibration
• G01S 7/497 - Means for monitoring or calibrating

Abstract

A composition including at least one XAP peptide, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase. Also, the use of a hydrolysate of at least one protein, the protein including or constituted by at least 0.05% to <5% or of at least 5% of XAP units, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase.

IPC Classes  ?

• A61K 38/06 - Tripeptides
• A23L 33/18 - Peptides; Protein hydrolysates
• A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/01 - Hydrolysed proteins; Derivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/05 - Dipeptides

Abstract

Mechanical transmission device and system comprising such a device. This mechanical transmission device (1) has a main axis (X1), characterized in that it comprises: – a support (3); – first (5) and second (6) input members, independent of one another and arranged in parallel, and intended to be operated by associated engines, the first and second members having, with respect to the support, a single degree of freedom in rotation or in translation about or along a first axis (X5) and a second axis (X6) which are parallel to the main axis and arranged symmetrically on each side of the main axis (X1); - an output member (8) having, with respect to the support, a single degree of freedom in rotation about the main axis (X1) or about an axis orthogonal to the main axis (X1) and a single degree of freedom in translation along the main axis (X1); and, – a coupling means (9, 10, 91, 101) for coupling the input members to the output member.

IPC Classes  ?

• F16H 25/20 - Screw mechanisms
• F16H 37/16 - Gearings comprising primarily toothed or friction gearing, links or levers, and cams, or members of at least two of these three types with a driving or driven member which both rotates or oscillates on its axis and reciprocates
• B25J 9/10 - Programme-controlled manipulators characterised by positioning means for manipulator elements

Abstract

The invention relates to a method for the in vitro detection and identification of at least one target pathogen present in a biological sample, implementing a method of gene capturing coupled with high-throughput sequencing, the gene-capturing method allowing the capture of DNA fragments having a length of at least 6000 pairs of bases.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Abstract

The invention relates to a method for the in vitro detection and identification of at least one microorganism involved in the process of degradation, modification or sequestration of at least one contaminant present in a biological sample, implementing a method of gene capturing coupled with high-throughput sequencing, the gene-capturing method allowing the capture of DNA fragments having a length of at least 6000 pairs of bases.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids